Clinical prognostic factors for fibrolamellar liver carcinoma

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Fibrolamellar liver carcinoma is a rare subtype of liver cancer with an unexplored etiology. There is no information about the choice of classification for fibrolamellar liver carcinoma (FLC) in the world literature, and data on the prognostic significance of clinical aspects in FLC are very contradictory and require further study.

AIM: To evaluate the practical significance of staging systems for operable hepatocellular cancer for fibrolamellar carcinoma (TNM/AJCC, BCLC) as a separate option, to study the influence of clinical aspects (disease stage, gender, age, size of tumor) of patients with FlC on the long-term results of their treatment.

MATERIALS AND METHODS: The retrospective study included 34 patients with FlC who underwent radical surgical treatment at the first stage at the Blokhin National Research Institute of Oncology of the Ministry of Health of the Russian Federation from 2005 to 2020.

RESULTS: When assessing the prevalence of the disease according to the TNM-8/AJCC system, a significant correlation between the FlC stage and the prognosis was revealed. It is proved that the greatest RFS was achieved in the group of stages II–IIIB, while the smallest RFS was achieved in the group with stage IVB (p=0.002; p=0.000). The highest OS was achieved in the group of stages II–IIIB, while the lowest OS was achieved in the group with stage IVB (p=0.050; p=0.000). The OV of patients with FlC was not dependent

CONCLUSIONS: The TNM-8/AJCC classification optimally predicts the results of surgical treatment of FlC. The use of the Barcelona staging system for this subtype of liver cancer is impractical. The size of the primary tumor, as part of the FlC staging system, turned out to be an independent prognostic factor. The age of the patient ≥20 years correlates with the deterioration of OV.

Full Text

Restricted Access

About the authors

Elena Yu. Antonova

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: elenaantonova5@mail.ru
ORCID iD: 0000-0002-9740-3839
SPIN-code: 6335-7053

PhD student of the  Department of Medicinal Treatment (Chemotherapy № 17 Department)

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478

Ekaterina A Moroz

Blokhin National Medical Research Center of Oncology

Email: moroz-kate@yandex.ru
ORCID iD: 0000-0002-6775-3678

MD, Cand. Sci. (Med.)

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478

Daniil V. Podlyzny

Blokhin National Medical Research Center of Oncology

Email: dr.podluzhny@mail.ru
ORCID iD: 0000-0001-7375-3378

MD, Cand. Sci. (Med.)

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478

Nikolai E. Kudashkin

Blokhin National Medical Research Center of Oncology

Email: dr.kudashkin@mail.ru
ORCID iD: 0000-0003-0504-585X

MD, Cand. Sci. (Med.)

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478

Aleksandr Yu. Volkov

Pletnev City Clinical Hospital

Email: 79164577128@yandex.ru
ORCID iD: 0000-0003-4412-2256
SPIN-code: 3013-4392

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Irina A. Dzhanyan

Blokhin National Medical Research Center of Oncology

Email: i-dzhanyan@mail.ru
ORCID iD: 0000-0002-6323-511X
SPIN-code: 5693-4504

Surgeon, Department of Medicinal Treatment (Chemotherapy No.17 Department)

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478

Konstantin K. Laktionov

Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University

Email: lkoskos@mail.ru
ORCID iD: 0000-0003-4469-502X
SPIN-code: 7404-5133

MD, Dr. Sci. (Med.), Prof.

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478; Moscow

Valery V. Breder

Blokhin National Medical Research Center of Oncology

Email: vbreder@yandex.ru
ORCID iD: 0000-0002-6244-4294
SPIN-code: 9846-4360

MD, Dr. Sci. (Med.)

Russian Federation, 24, Kashirskoe Shosse, Moscow, 115478

References

  1. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91(2):168–186. doi: 10.1001/archpedi.1956.02060020170015
  2. Darcy DG, Malek MM, Kobos R, et al. Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg. 2015;50(1):153–156. doi: 10.1016/j.jpedsurg.2014.10.039
  3. Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820–830. doi: 10.1016/j.jamcollsurg.2012.08.001
  4. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26(4):877–883. doi: 10.1002/hep.510260412
  5. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803. doi: 10.1002/hep.20096
  6. Hemming AW, Langer B, Sheiner P, et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997;1(4):342–346. doi: 10.1016/s1091-255x(97)80055-8
  7. Smith M, Tomboc PJ, Markovich B. Fibrolamellar Hepatocellular Carcinoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
  8. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106(6):1331–1338. doi: 10.1002/cncr.21703
  9. Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6(1):3–9. PMC3597938
  10. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343(6174):1010–1014. doi: 10.1126/science.1249484
  11. Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28(6):822–829. doi: 10.1038/modpathol.2015.4
  12. Hemming AW, Langer B, Sheiner P, et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997;1(4):342-346. doi: 10.1016/s1091-255x(97)80055-8
  13. Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo). 2012;2012:743790. doi: 10.6064/2012/743790
  14. Dinh TA, Vitucci EC, Wauthier E, et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Sci Rep. 2017;7:44653. doi: 10.1038/srep44653

Supplementary files

Supplementary Files
Action
1. Fig. 1. Progression-free survival of patients with FLC depending on the stage of the disease according to the TNM/AJCC system. The Kaplan-Meier method.

Download (109KB)
2. Fig. 2. Overall survival of patients with FLC depending on the stage of the disease according to the TNM-8 system. The Kaplan-Meier method.

Download (107KB)
3. Fig. 3. Overall survival of patients depending on age in FLC. The Kaplan-Meier method

Download (106KB)
4. Fig. 4. Progression-free survival of patients with FLC depending on the size of the primary tumor. The Kaplan-Meier method

Download (101KB)
5. Fig. 5. Overall survival of patients with FLC depending on the size of the primary tumor. The Kaplan-Meier method

Download (104KB)

Copyright (c) 2021 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies